{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T05:05:42Z","timestamp":1733547942624,"version":"3.30.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,5]]},"DOI":"10.7759\/cureus.75193","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T07:55:14Z","timestamp":1733471714000},"source":"Crossref","is-referenced-by-count":0,"title":["A Case of Chronic Myelomonocytic Leukemia With Recurrent Skin Involvement"],"prefix":"10.7759","author":[{"given":"Eren","family":"Arslan Davulcu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suat Hilal","family":"Ak\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber DA","year":"2022","unstructured":"Arber DA, Orazi A, Hasserjian RP, et al.. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022, 140:1200-28. 10.1182\/blood.2022015850","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31825dd4de","article-title":"Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases","volume":"36","author":"Vitte F","year":"2012","unstructured":"Vitte F, Fabiani B, B\u00e9net C, et al.. Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases. Am J Surg Pathol. 2012, 36:1302-16. 10.1097\/PAS.0b013e31825dd4de","journal-title":"Am J Surg Pathol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.05.003","article-title":"Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature","volume":"36","author":"Mathew RA","year":"2012","unstructured":"Mathew RA, Bennett JM, Liu JJ, et al.. Cutaneous manifestations in CMML: Indication of disease acceleration or transformation to AML and review of the literature. Leuk Res. 2012, 36:72-80. 10.1016\/j.leukres.2011.05.003","journal-title":"Leuk Res"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/cup.13957","article-title":"Atypical cutaneous histiocytic eruption in a patient with chronic myelomonocytic leukemia: A case report","volume":"48","author":"Li JJ","year":"2021","unstructured":"Li JJ, Talam S, Star P, Getta B. Atypical cutaneous histiocytic eruption in a patient with chronic myelomonocytic leukemia: A case report. J Cutan Pathol. 2021, 48:680-8. 10.1111\/cup.13957","journal-title":"J Cutan Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.1986.tb00086.x","article-title":"Monocytic skin infiltration in chronic myelomonocytic leukaemia","volume":"8","author":"Copplestone JA","year":"1986","unstructured":"Copplestone JA, Oscier DG, Mufti GJ, Hamblin TJ. Monocytic skin infiltration in chronic myelomonocytic leukaemia. Clin Lab Haematol. 1986, 8:115-9. 10.1111\/j.1365-2257.1986.tb00086.x","journal-title":"Clin Lab Haematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2016.05.013","article-title":"Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review","volume":"47","author":"Grignano E","year":"2016","unstructured":"Grignano E, Mekinian A, Braun T, et al.. Autoimmune and inflammatory diseases associated with chronic myelomonocytic leukemia: A series of 26 cases and literature review. Leuk Res. 2016, 47:136-41. 10.1016\/j.leukres.2016.05.013","journal-title":"Leuk Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic\u00a0Neoplasms","volume":"36","author":"Khoury JD","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, et al.. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic\u00a0Neoplasms. Leukemia. 2022, 36:1703-19. 10.1038\/s41375-022-01613-1","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-714030","article-title":"Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia","volume":"128","author":"Elena C","year":"2016","unstructured":"Elena C, Gall\u00ec A, Such E, et al.. Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood. 2016, 128:1408-17. 10.1182\/blood-2016-05-714030","journal-title":"Blood"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-607341","article-title":"An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults","volume":"125","author":"Savona MR","year":"2015","unstructured":"Savona MR, Malcovati L, Komrokji R, et al.. An international consortium proposal of uniform response criteria for myelodysplastic\/myeloproliferative neoplasms (MDS\/MPN) in adults. Blood. 2015, 125:1857-65. 10.1182\/blood-2014-10-607341","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06707.x","article-title":"Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition","volume":"138","author":"Choi SH","year":"2007","unstructured":"Choi SH, Byun HM, Kwan JM, Issa JP, Yang AS. Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol. 2007, 138:616-23. 10.1111\/j.1365-2141.2007.06707.x","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279500","article-title":"How I diagnose and treat chronic myelomonocytic leukemia","volume":"107","author":"Patnaik MM","year":"2022","unstructured":"Patnaik MM. How I diagnose and treat chronic myelomonocytic leukemia. Haematologica. 2022, 107:1503-17. 10.3324\/haematol.2021.279500","journal-title":"Haematologica"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson R","year":"2013","unstructured":"Itzykson R, Kosmider O, Renneville A, et al.. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013, 31:2428-36. 10.1200\/JCO.2012.47.3314","journal-title":"J Clin Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.82","article-title":"Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance","volume":"6","author":"Patnaik MM","year":"2016","unstructured":"Patnaik MM, Zahid MF, Lasho TL, et al.. Number and type of TET2 mutations in chronic myelomonocytic leukemia and their clinical relevance. Blood Cancer J. 2016, 6:e472. 10.1038\/bcj.2016.82","journal-title":"Blood Cancer J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003345","article-title":"SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival","volume":"4","author":"Wudhikarn K","year":"2020","unstructured":"Wudhikarn K, Loghavi S, Mangaonkar AA, et al.. SF3B1-mutant CMML defines a predominantly dysplastic CMML subtype with a superior acute leukemia-free survival. Blood Adv. 2020, 4:5716-21. 10.1182\/bloodadvances.2020003345","journal-title":"Blood Adv"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"Ricci C","year":"2010","unstructured":"Ricci C, Fermo E, Corti S, et al.. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res. 2010, 16:2246-56. 10.1158\/1078-0432.CCR-09-2112","journal-title":"Clin Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23186-w","article-title":"RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis","volume":"12","author":"Carr RM","year":"2021","unstructured":"Carr RM, Vorobyev D, Lasho T, et al.. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun. 2021, 12:2901. 10.1038\/s41467-021-23186-w","journal-title":"Nat Commun"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/276890-a-case-of-chronic-myelomonocytic-leukemia-with-recurrent-skin-involvement","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T07:55:15Z","timestamp":1733471715000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/276890-a-case-of-chronic-myelomonocytic-leukemia-with-recurrent-skin-involvement"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.75193","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,5]]}}}